Evidence map›Paper›PMID 26243222›Full record

ArticleStroke2015

Neurorestorative Therapy of Stroke in Type 2 Diabetes Mellitus Rats Treated With Human Umbilical Cord Blood Cells.

Tao Yan, Poornima Venkat, Michael Chopp, Alex Zacharek, Ruizhuo Ning, Yisheng Cui, Cynthia Roberts, Nicole Kuzmin-Nichols, Cyndy Davis Sanberg, Jieli Chen

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stroke, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
5.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Locoregional delivery of stem cell-based therapies.Science translational medicine · 2020
    Review
  15. Inflammatory responses mediate brain-heart interaction after ischemic stroke in adult mice.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2020
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Role of microRNA-126 in vascular cognitive impairment in mice.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Tao YanFrom the Department of Neurology, Henry Ford Hospital, Detroit, MI (T.Y., P.V., M.C., A.Z., R.N., Y.C., C.R., J.C.); Tianjin Neurological Institute, Neurology of Tianjin Medical University General Hospital, Tianjin, China (T.Y., J.C.); Department of Physics, Oakland University, Rochester, MI (P.V., M.C.); and Saneron CCEL Therapeutics Inc, Tampa, FL (N.K.-N., C.D.S.).
Poornima VenkatFrom the Department of Neurology, Henry Ford Hospital, Detroit, MI (T.Y., P.V., M.C., A.Z., R.N., Y.C., C.R., J.C.); Tianjin Neurological Institute, Neurology of Tianjin Medical University General Hospital, Tianjin, China (T.Y., J.C.); Department of Physics, Oakland University, Rochester, MI (P.V., M.C.); and Saneron CCEL Therapeutics Inc, Tampa, FL (N.K.-N., C.D.S.).
Michael ChoppFrom the Department of Neurology, Henry Ford Hospital, Detroit, MI (T.Y., P.V., M.C., A.Z., R.N., Y.C., C.R., J.C.); Tianjin Neurological Institute, Neurology of Tianjin Medical University General Hospital, Tianjin, China (T.Y., J.C.); Department of Physics, Oakland University, Rochester, MI (P.V., M.C.); and Saneron CCEL Therapeutics Inc, Tampa, FL (N.K.-N., C.D.S.).
Alex ZacharekFrom the Department of Neurology, Henry Ford Hospital, Detroit, MI (T.Y., P.V., M.C., A.Z., R.N., Y.C., C.R., J.C.); Tianjin Neurological Institute, Neurology of Tianjin Medical University General Hospital, Tianjin, China (T.Y., J.C.); Department of Physics, Oakland University, Rochester, MI (P.V., M.C.); and Saneron CCEL Therapeutics Inc, Tampa, FL (N.K.-N., C.D.S.).
Ruizhuo NingFrom the Department of Neurology, Henry Ford Hospital, Detroit, MI (T.Y., P.V., M.C., A.Z., R.N., Y.C., C.R., J.C.); Tianjin Neurological Institute, Neurology of Tianjin Medical University General Hospital, Tianjin, China (T.Y., J.C.); Department of Physics, Oakland University, Rochester, MI (P.V., M.C.); and Saneron CCEL Therapeutics Inc, Tampa, FL (N.K.-N., C.D.S.).
Yisheng CuiFrom the Department of Neurology, Henry Ford Hospital, Detroit, MI (T.Y., P.V., M.C., A.Z., R.N., Y.C., C.R., J.C.); Tianjin Neurological Institute, Neurology of Tianjin Medical University General Hospital, Tianjin, China (T.Y., J.C.); Department of Physics, Oakland University, Rochester, MI (P.V., M.C.); and Saneron CCEL Therapeutics Inc, Tampa, FL (N.K.-N., C.D.S.).
Cynthia RobertsFrom the Department of Neurology, Henry Ford Hospital, Detroit, MI (T.Y., P.V., M.C., A.Z., R.N., Y.C., C.R., J.C.); Tianjin Neurological Institute, Neurology of Tianjin Medical University General Hospital, Tianjin, China (T.Y., J.C.); Department of Physics, Oakland University, Rochester, MI (P.V., M.C.); and Saneron CCEL Therapeutics Inc, Tampa, FL (N.K.-N., C.D.S.).
Nicole Kuzmin-NicholsFrom the Department of Neurology, Henry Ford Hospital, Detroit, MI (T.Y., P.V., M.C., A.Z., R.N., Y.C., C.R., J.C.); Tianjin Neurological Institute, Neurology of Tianjin Medical University General Hospital, Tianjin, China (T.Y., J.C.); Department of Physics, Oakland University, Rochester, MI (P.V., M.C.); and Saneron CCEL Therapeutics Inc, Tampa, FL (N.K.-N., C.D.S.).
Cyndy Davis SanbergFrom the Department of Neurology, Henry Ford Hospital, Detroit, MI (T.Y., P.V., M.C., A.Z., R.N., Y.C., C.R., J.C.); Tianjin Neurological Institute, Neurology of Tianjin Medical University General Hospital, Tianjin, China (T.Y., J.C.); Department of Physics, Oakland University, Rochester, MI (P.V., M.C.); and Saneron CCEL Therapeutics Inc, Tampa, FL (N.K.-N., C.D.S.).
Jieli ChenFrom the Department of Neurology, Henry Ford Hospital, Detroit, MI (T.Y., P.V., M.C., A.Z., R.N., Y.C., C.R., J.C.); Tianjin Neurological Institute, Neurology of Tianjin Medical University General Hospital, Tianjin, China (T.Y., J.C.); Department of Physics, Oakland University, Rochester, MI (P.V., M.C.); and Saneron CCEL Therapeutics Inc, Tampa, FL (N.K.-N., C.D.S.). jieli@neuro.hfh.edu.
Tianjin Medical University General Hospital · CNOakland University · US

Funding

Neurorestorative therapy of stroke with HUCBC in type two diabetic miceR01NS083078 · NINDS · HENRY FORD HEALTH SYSTEM · PI CHEN, JIELI · 2014 to 2018
$1.6M
MSCs Induce Brain Plasticity via tPAR01AG037506 · NIA · HENRY FORD HEALTH SYSTEM · PI CHOPP, MICHAEL · 2011 to 2015
$1.5M
Neurorestorative therapy of stroke with agents that increase HDLR01AG031811 · NIA · HENRY FORD HEALTH SYSTEM · PI CHEN, JIELI · 2009 to 2013
$1.4M
Neurorestorative therapy of stroke with HUCBC in T2DM ratsR41NS080329 · NINDS · SANERON CCEL THERAPEUTICS, INC. · PI CHEN, JIELI · 2013 to 2014
$423k
NIA NIH HHS R01 AG031811NIA NIH HHS R01AG031811NIA NIH HHS R01 AG 037506NIA NIH HHS R01 AG037506NINDS NIH HHS R01 NS083078NINDS NIH HHS R01NS083078-01A1NINDS NIH HHS R41 NS080329NINDS NIH HHS R41NS080329-01A1
6 · The paper itself

Abstract

background and purposeDiabetes mellitus is a high-risk factor for ischemic stroke. Diabetic stroke patients suffer worse outcomes, poor long-term recovery, risk of recurrent strokes, and extensive vascular damage. We investigated the neurorestorative effects and the underlying mechanisms of stroke treatment with human umbilical cord blood cells (HUCBCs) in type 2 diabetes mellitus (T2DM) rats.

methodsAdult male T2DM rats were subjected to 2 hours of middle cerebral artery occlusion (MCAo). Three days after MCAo, rats were treated via tail-vein injection with (1) PBS and (2) HUCBCs (5×10(6)), n=10 per group.

resultsHUCBC stroke treatment initiated 3 days after MCAo in T2DM rats did not significantly decrease blood-brain barrier leakage (P=0.1) and lesion volume (P=0.078), but significantly improved long-term functional outcome and decreased brain hemorrhage (P<0.05) when compared with the PBS-treated T2DM MCAo control group. HUCBC treatment significantly promoted white matter remodeling as indicated by increased expression of Bielschowsky silver (axons marker), Luxol fast blue (myelin marker), SMI-31 (neurofilament), and Synaptophysin in the ischemic border zone. HUCBC promoted vascular remodeling and significantly increased arterial and vascular density. HUCBC treatment of stroke in T2DM rats significantly increased M2 macrophage polarization (increased M2 macrophage, CD163and CD 206; decreased M1 macrophage, ED1 and inducible nitric oxide synthase expression) in the ischemic brain compared with PBS-treated T2DM MCAo controls (P<0.05). HUCBC also significantly decreased proinflammatory factors, that is, matrix metalloproteinase 9, receptor for advanced glycation end products and toll-like receptor 4 expression in the ischemic brain.

conclusionsHUCBC treatment initiated 3 days after stroke significantly increased white matter and vascular remodeling in the ischemic brain as well as decreased neuroinflammatory factor expression in the ischemic brain in T2DM rats and promoted M2 macrophage polarization. HUCBC reduction of neuroinflammation and increased vascular and white matter axonal remodeling may contribute to the HUCBC-induced beneficial effects in T2DM stroke rats.

Indexed as

AnimalsBrain IschemiaCord Blood Stem Cell TransplantationDiabetes Mellitus, Type 2Disease Models, AnimalHumansInfarction, Middle Cerebral ArteryMaleRatsRats, WistarStrokediabetes mellitus, type 2human umbilical cord bloodinfarction, middle cerebral arterymatrix metalloproteinase 9neurorestorative therapystrokevascular remodeling

Identifiers

PMID26243222
PMCPMC4550506
OpenAlexW1833535161

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.